![John Bell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Bell
Président chez
IMMUNOCORE HOLDINGS PLC
Fortune : 388 628 $ au 31/05/2026
Profil
John Irving Bell is the founder of The Wellcome Trust Centre for Human Genetics, founded in 1993.
Dr. Bell was the founder of Oxagen Ltd., founded in 1997, and served as Non-Executive Director from 1997 to 2017.
Dr. Bell is also the founder of Powderject Pharmaceuticals Plc,Avidex Ltd...
Dr. Bell is currently Co-Chief Executive Officer at Ellison Institute of Technology since 2024.
Dr. Bell is Chairman-Partnership Board at Oxford Centre for Diabetes Endocrinology & Metabolism since 1999.
Dr. Bell is Chairman at The Oxford Health Alliance, GMEC Management Co. Ltd., Office for Strategic Co-ordination of Health Research, and Immunocore Holdings Plc since 2015.
Dr. Bell is Non-Executive Director at The Jenner Institute Laboratories since 2013, Oxford University Hospitals NHS Trust, The Gray Laboratory Cancer Research Trust, Genomics England Ltd., and Oxford Science Enterprises PLC.
Dr. Bell is Trustee at Rhodes Trust, The Ewelme Almshouse Charity, and Our Future Health Uk.
Dr. Bell is Advisor at Biospring Management Partners LP.
Former jobs include Chairman at Arcturis Data Ltd., Director at Genentech, Inc. and Atopix Therapeutics Ltd., Non-Executive Director at Roche Holding AG from 2011 to 2020, and at F.
Hoffmann-La Roche Ltd. Dr. Bell was President of the Academy of Medical Sciences from 2006 to 2011.
Dr. Bell was Professor at the University of Oxford from 2002 to 2024.
Education includes a doctorate conferred in 1990 and an undergraduate degree conferred in 1979 from Magdalen College School Oxford Ltd, and an undergraduate degree conferred in 1975 from the University of Alberta.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNOCORE HOLDINGS PLC 0,03 % | 27/05/2026 | 13 452 ( 0,03 % ) | 388 628 $ | 31/05/2026 |
Postes actifs de John Bell
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOCORE HOLDINGS PLC | Président | - |
The Ewelme Almshouse Charity | Directeur/Membre du Conseil | - |
Our Future Health Uk
 Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Provides support services | Directeur/Membre du Conseil | - |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Directeur/Membre du Conseil | - |
Biospring Management Partners LP
 Biospring Management Partners LP Investment ManagersFinance Biospring Partners invests in companies located in the United States. The firm focuses on the tech-enabled pharma services sector. It provides financing for buyout and growth stage capital requirements. | Consultant / Advisor | - |
Office for Strategic Co-ordination of Health Research | Président | - |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Operates genomes project in research and health care for patients with cancer and rare diseases and their families | Directeur/Membre du Conseil | - |
Rhodes Trust | Directeur/Membre du Conseil | - |
GMEC Management Co. Ltd. | Président | - |
| ░░░ ░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ | - |
Anciens postes connus de John Bell
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de John Bell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
27
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 27 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Powderject Pharmaceuticals Plc
 Powderject Pharmaceuticals Plc Medical SpecialtiesHealth Technology Develops pharmaceutical products | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Magdalen College School Oxford Ltd
 Magdalen College School Oxford Ltd Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Develops novel molecule drugs to treat inflammatory and respiratory diseases | Health Technology |
Avidex Ltd.
 Avidex Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers drugs for the treatment of cancer and autoimmune diseases | Health Technology |
Rhodes Trust | |
University of Alberta
 University of Alberta Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Academy of Medical Sciences
 Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services Provides biomedical and health research services | Commercial Services |
The Jenner Institute Laboratories
 The Jenner Institute Laboratories Miscellaneous Commercial ServicesCommercial Services Develops vaccines against major global diseases | Commercial Services |
The Wellcome Trust Centre for Human Genetics | |
Oxford Centre for Diabetes Endocrinology & Metabolism | |
Oxford University Hospitals NHS Trust
 Oxford University Hospitals NHS Trust Investment Trusts/Mutual FundsMiscellaneous Provides trust services | Miscellaneous |
The Gray Laboratory Cancer Research Trust
 The Gray Laboratory Cancer Research Trust Investment Trusts/Mutual FundsMiscellaneous Provides trust services | Miscellaneous |
The Oxford Health Alliance
 The Oxford Health Alliance Miscellaneous Commercial ServicesCommercial Services Operates charitable company that engages in prevention of chronic diseases | Commercial Services |
GMEC Management Co. Ltd. | |
The Ewelme Almshouse Charity | |
Atopix Therapeutics Ltd.
 Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops a novel class of medicines to treat atopic dermatitis and severe asthma | Health Technology |
Genomics England Ltd.
Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Operates genomes project in research and health care for patients with cancer and rare diseases and their families | Commercial Services |
Office for Strategic Co-ordination of Health Research | |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises invests in companies located in the United Kingdom. The firm targets companies operating in the fields of health tech, deep tech, and life sciences sectors. It provides financing for seed and early stage capital requirements with an investment size of GBP 0.1 – 10 million. | Finance |
Sensyne Health Ltd.
 Sensyne Health Ltd. Miscellaneous Commercial ServicesCommercial Services Provides statistical analyses and advanced insights to the healthcare industry | Commercial Services |
Biospring Management Partners LP
Biospring Management Partners LP Investment ManagersFinance Biospring Partners invests in companies located in the United States. The firm focuses on the tech-enabled pharma services sector. It provides financing for buyout and growth stage capital requirements. | Finance |
Immunocore Holdings Plc
 Immunocore Holdings Plc BiotechnologyHealth Technology Operates as a biotechnology company which develops immunotherapies | Health Technology |
Our Future Health Uk
Our Future Health Uk Miscellaneous Commercial ServicesCommercial Services Provides support services | Commercial Services |
